Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1.
Somaiah N, Block M, Kim J, Shapiro G, Hwu P, Eder J, Jones R, Gnjatic S, Lu H, Hsu F, Pollack S. Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1. Journal Of Clinical Oncology 2015, 33: 3021-3021. DOI: 10.1200/jco.2015.33.15_suppl.3021.Peer-Reviewed Original Research